Rare bone disease often goes untreated while patients quietly live with chronic pain
Teeth and bones are among the hardest structures in the human body, but certain inherited conditions can rob them of that strength. One of them is hypophosphatasia (HPP), a rare, lifelong genetic bone disorder that disrupts the development of bones and teeth, leaving them unusually soft and fragile. A recent study set out to determine how common HPP is across Central and Eastern Europe and how it…
Hypophosphatasia (HPP) is an extremely rare, lifelong genetic bone disorder that weakens bones and teeth. A recent study analyzed medical records from 34 patients in five Central and Eastern European countries to determine how common and severe the condition is. The research revealed that more than 70% of these patients suffer constant bone and muscle pain, often requiring multiple pain medications daily.
Despite the debilitating nature of HPP, only one patient in the study was receiving asfotase alfa, an enzyme replacement therapy considered the standard treatment for the disease. The study also highlighted that HPP symptoms can vary greatly, with childhood-onset cases more likely to develop bone deformities, frequent fractures, and early tooth loss, while adult-onset cases often experience persistent pain and joint issues.
Respiratory complications and kidney problems were also common among patients. The study emphasizes the urgent need for better awareness and access to treatment for this rare disease.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
